2. Search Result
Search Result
Results for "

complex V

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Natural
Products

7

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152949
    Myosin V-IN-1

    		Myosin Neurological Disease
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex .
    Myosin V-IN-1
  • HY-130257
    CP5V

    		PROTACs Cancer
    CP5V is a PROTAC connected by ligands for von Hippel-Lindau and CDK, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation .
    CP5V
  • HY-N6782
    Oligomycin
    55+ Cited Publications

    		 Oxidative Phosphorylation ATP Synthase Fungal Antibiotic Infection Cancer
    Oligomycin, an antifungal antibiotic, is an inhibitor of H +-ATP-synthase. Oligomycin blocks oxidative phosphorylation and the electron transport chain. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells .
    Oligomycin
  • HY-12343
    ML277

    CID-53347902

    		 Potassium Channel Cardiovascular Disease
    ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes .
    ML277
  • HY-E70542
    Bovine Factor V/Va

    		Biochemical Assay Reagents Cardiovascular Disease
    Bovine Factor V/Va can be purified from fresh bovine plasma and used as a source of V/Va in the prothrombinase complex.
    Bovine Factor V/Va
  • HY-173629
    RMC-5127

    		Ras Apoptosis Cancer
    RMC-5127 is an orally active and brain-penetrant mutant-selective tri-complex RAS G12V inhibitor. RMC-5127 non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding . RMC-5127 inhibits the RAS pathway in KRAS G12V mutant cancer cells, reducing cell proliferation and inducing apoptosis. RMC-5127 is promising for research of cancers with RAS mutations, such as non-small cell lung cancer .
    RMC-5127
  • HY-W614725
    Apcin-A monohydrochloride

    		APC Ligands for Target Protein for PROTAC Cancer
    Apcin-A monohydrochloride, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A monohydrochloride interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A monohydrochloride can be used to synthesize the PROTAC CP5V (HY-130257) .
    Apcin-A monohydrochloride
  • HY-155474
    Me4Phen

    		Apoptosis Cancer
    Me4Phen (compound 3) is an oxygen rhenium (V) complex that depletes mitochondrial membrane potential and upregulates intracellular reactive oxygen species (ROS), leading to endoplasmic reticulum stress-mediated necrosis of cancer cells. Me4Phen is highly lipophilic and effectively overcomes Cisplatin (HY-17394) resistance in a variety of cancer cells .
    Me4Phen
  • HY-173364
    EB-TCIP

    BAK-04-212

    		 BCL6 Cancer
    EB-TCIP (BAK-04-212) is a bivalent molecule comprised of AP1867 (HY-114434) and BI-3812 (HY-111381). EB-TCIP can form a reversible ternary complex between FKBP F36V and BCL6 BTB. EB-TCIP recruits FKBP12 F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, leading to rapid expression of BCL6 target genes (eg: SOCS2 and CXCL11). EWS/FLI1 is a fusion transcription factors in Ewing sarcoma. EB-TCIP can be used for research of deregulated transcription in cancer .
    EB-TCIP
  • HY-126634
    Lyngbyatoxin B

    		Others Infection
    Lyngbyatoxin B is a complex compound in a versatile biosynthetic pathway from the marine cyanobacterium Moorea producens. By heterologously expressing the lyngbyatoxin biosynthetic pathway in Escherichia coli, lyngbyatoxin A (25.6 mg/L) and its precursor indolactam-V (150 mg/L) were successfully produced. This approach confirmed the biosynthetic route of lyngbyatoxin and laid a chemical foundation for future pathway engineering. In addition, the successful production of lyngbyatoxin A in E. coli opens the possibility for heterologous expression and characterization of other cyanobacterial natural products.
    Lyngbyatoxin B
  • HY-156498
    RMC-7977
    2 Publications Verification

    		 Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP Cancer
    RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
    RMC-7977
  • HY-130841
    Apcin-A

    		APC Ligands for Target Protein for PROTAC Cancer
    Apcin-A is a small molecule inhibitor that selectively targets the cell division cycle protein Cdc20 and is a derivative of Apcin (HY-110287). Apcin-A competitively binds to the D-box binding pocket of Cdc20 and inhibits substrate ubiquitination mediated by the anaphase promoting complex APC/C-Cdc20. Apcin-A also blocks the binding of Cdc20 to substrates (such as securin and cyclin B1), inhibiting anaphase initiation and cell cycle exit. Apcin-A can promote or prolong mitotic slippage in coordination with p31 comet under conditions of high spindle assembly checkpoint (SAC) activity. Apcin-A can be used to develop anti-mitotic drugs and overcome tumor chemotherapy resistance. Apcin-A can be used to synthesize PROTAC CP5V (HY-130257)[1][2][3].
    Apcin-A
  • HY-169385
    ATC-324

    		AUTOTACs Androgen Receptor Cancer
    ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
    ATC-324

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: